ClinicalTrials.gg
CompletedNCT07951801MFR CBT TTHUpdated Nov 20, 2026

Effects of Myofascial Release and Cognitive Behavioral Therapy on Stress and Neck Disability in Patients With Tension-Type Headache

An interventional study of MFR and Cognitive Behavior Therapy in Tension Type Headache, Myofascial Release Technique and Cognitive Behavior Therapy, sponsored by Dow University of Health Sciences. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Dow University of Health Sciences · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jun 2025, registered Nov 2026).
Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The goal of the study was to determine the effectiveness of myofascial release and cognitive behavior therapy in reducing stress, anxiety, depression, and neck disability in tension-type headache. The aim is to answer:

- Does the combination of myofascial release and cognitive behavior therapy reduce stress, anxiety, depression, and neck disability in TTH patients?

Participants were:

  • given MFR and CBT intervention in the experimental group for 4 weeks (twice a week).
  • MFR and a talking control intervention were given to the control group for 4 weeks (twice a week).
Read the detailed description

Background:

TTH is a mild-to-moderate intensity pain that feels like a tight band around the forehead, occiput, neck, and behind the eyes, with bilateral localization, and is not aggravated by any physical activity or related to nausea or vomiting. In addition, TTH patients may have discomfort when exposed to light or noise, but not simultaneously. According to the International Classification of Headache Disorders (ICHD) of 2018, TTH is divided into three types based on the frequency of episodes: infrequent episodic TTH (\< 1 day/month on average), frequent episodic TTH (1- 14 days/month on average), and chronic TTH (>15days/month on average).

The global prevalence of tension-type headaches is approximately 26.0% (22.7 - 29.5%). Globally, TTH incidence showed an overall upward trend from 1990 to 2019(4). An observed 1-year prevalence of TTH in Pakistan is around 44.7%. This is significantly higher than the global prevalence of TTH (5, 6). TTH in Pakistan appears to be more common among younger and middle-aged adults, with the highest prevalence reported in the 20-49 years age group. The prevalence tends to decrease in older age groups, but remains significant. Males are more prone to have TTH as compared to females, with a ratio of 4:3.

Myofascial release therapy will target the peripheral pain origin. MFR releases tension or restriction in the muscles by restoring their optimal length, decreasing pain, and improving function. It is a hands-on technique that treats pain as well as emotional bracing and holding patterns. Cognitive behavior therapy (CBT) focuses on behavior, cognition, and emotions. In the context of cognition, CBT helps individuals recognize negative thoughts that cause depression and anxiety. Then it assists in modifying negative thoughts and maladaptive thinking patterns. CBT includes behavioral activation and problem-solving techniques, which encourage individuals to replace negative behavior with positive behaviors and maintain them, which helps reduce anxiety and depression.

Because TTH has a complex pathophysiology, it is necessary to address both central and peripheral pain mechanisms. It is still unknown how well multidisciplinary collaborations like myofascial release therapy (a physiotherapy technique) with cognitive behavioral therapy (a psychotherapy technique) are effective in reducing stress, anxiety, depression, neck disability, and episodes of TTH. Although previous studies have shown the potential benefits of MRF and CBT for neck pain and psychological disorders, their relative effectiveness in the context of TTH has not been fully examined. A well-designed RCT is necessary to evaluate the effect of these two therapies in lowering stress and neck disability in individuals suffering from tension-type headaches, as indicated by the gap in this research.

METHODOLOGY Sample Description

Inclusion Criteria

  • Male and Female
  • Diagnosed with tension-type headache by a neurologist according to the International Headache Classification.
  • Age 18 - 45(26, 27).

Exclusion Criteria

  • Cervical radiculopathy
  • Migraine or any other type of headache
  • Cervical injury or trauma
  • Brain tumor

Research Design The current study was a double-blind randomized controlled trial. The experimental group received myofascial release therapy and cognitive behavioral therapy, while the control group received MFR with placebo psychotherapy. The control group received talking control therapy. These were client-led sessions, did not challenge the patient's emotions, and had no core elements of CBT. This placebo psychotherapy was used to blind the participants to the nature of therapy. The assessor, who assessed the patients at the end of 4 weeks intervention and after 3 months follow up were blinded from the nature of treatment.

Data Collection Data collection started after approval from the IRB of Dow University of Health Sciences. The subjects were taken from the outpatient physiotherapy department referred by the neurologist. Before enrolling, the patient was screened and met the eligibility criteria. Patients between age 18 to 45year was taken. The purpose, objective of the study, information, risks, and possible benefits were explained to the patients by the therapist through an informed consent sheet. Each selected subject underwent random allocation to one of the two treatment groups with different interventions, i.e., experimental and control group, with the help of a computer-generated randomization sheet. Group A received MFR (Myofascial Release Therapy) + isometrics of neck muscles (physical therapy intervention) and CBT (Cognitive Behavioral Therapy). In contrast, group B (the control group) received MFR (Myofascial Release Therapy) + isometrics of neck muscles + placebo psychotherapy (talking control group). A hot pack was applied to both groups. Assessment was done at baseline and was re-evaluated after the completion of the 8th session by a therapist other than the principal investigator, who was blind to the patients' type of treatment. The follow-up of the patients was done after 3 months of treatment. The participants followed the home exercise plan for three months with same intensity and duration. The outcome measures were NPRS to measure headache intensity, the daily headache diary to monitor headache frequency and duration, NDI to assess neck disability, and DASS-21 to assess anxiety, depression, and stress. A total of 8 sessions of each therapy (MFR and CBT) were provided, each lasting 45 minutes. The professional clinical psychologist at the DIPM\&R OPD setting provided two sessions per week, with 45 minutes per session.

Setting Physiotherapy OPD at DIPMR, Ojha Hospital, Karachi, Pakistan.

Sample Size Open Epi online software was used to calculate the sample size. An independent sample t-test using the mean and SD of the Neck Disability Index at 4 weeks was 11.366±3.952 in Group MRT and CBT, and 9.322±4.407 in Group MRT alone(48), 95% confidence level and 80% power of the test. The sample size was 54 (27 cases and 27 controls) using the Fleiss method with continuity correction. After including a 15% dropout rate, a total of 54 patients were recruited and divided into 27 patients in each group (MFR+CBT = 27, MFR = 27)

Sampling Technique Non-probability purposive sampling technique.

Outcome Measures The outcome measures will be assessed at baseline and post-intervention, i.e., after 8 sessions.

Primary Outcomes:

  • DASS-21 will be used to assess the Depression, Anxiety, and Stress scores.
  • Neck disability will be assessed by the Neck Disability Index (NDI)

Secondary Outcomes:

  • Headache frequency, intensity, and duration
  • Pain intensity assessed by the Numeric Pain Rating Scale
02

Conditions studied

  • Tension Type Headache
  • Myofascial Release Technique
  • Cognitive Behavior Therapy

Keywords

  • tension type headache
  • myofascial release therapy
  • cognitive behavior therapy
  • neck disability
  • depression
  • anxiety
03

In context

Tension-Type Headache

144 studies on the registry are indexed under Tension-Type Headache; 42 are open to participants now.

This study's enrollment of 54 is close to the median of 60 across 108 interventional studies indexed under Tension-Type Headache.

Browse Tension-Type Headache studies →

Lead sponsor

Dow University of Health Sciences is the lead sponsor of 179 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Female
  • Diagnosed with tension-type headache by a neurologist according to the International Headache Classification.
  • Age 18 - 45(25, 26)

Exclusion criteria

Exclusion Criteria:

  • Cervical radiculopathy
  • Migraine or any other type of headache
  • Cervical injury or trauma
  • Brain tumor
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Experimental Group

    Experimental Group: MFR + CBT + Neck Isometrics

    Other: MFR · Behavioral: Cognitive Behavior Therapy

  • Experimental
    Control Group

    Control Group: MFR + Talking control(placebo psychotherapy) + Neck Isometrics

    Other: MFR · Other: Talking Control (Placebo Psychotherapy)

Interventions

  • OtherMFR

    MFR: Myofascial release therapy will target the peripheral pain origin. MFR releases tension or restriction in the muscles by restoring their optimal length, decreasing pain, and improving function. It is a hands-on technique that treats pain as well as emotional bracing and holding patterns. Some speculate that restriction in one part of the body produces tension in other parts due to its continuity.

  • BehavioralCognitive Behavior Therapy

    CBT: CBT includes behavioral activation and problem-solving techniques, which encourage individuals to replace negative behaviors with positive behaviors and maintain positive behaviors, which help reduce anxiety and depression.

  • OtherTalking Control (Placebo Psychotherapy)

    Talking Control(Placebo Psychotherapy): In this study, placebo psychotherapy was used to blind the patients in a control group. Talking control does not include any specific CBT elements. Talking control (TC) consists of client-led sessions and covers topics that challenge patients' beliefs or emotions. It includes health, religion, and TV programs.

06

What researchers measure

Primary outcomes

  1. Depression, Anxiety, Stress Scale (DASS- 21)

    DASS-21 is commonly used to assess depression, anxiety, and stress. It consists of three subscales: depression, anxiety, and stress

    Time frame: 4 weeks

  2. Neck Disability Index (NDI)

    The NDI assesses how neck pain affects individuals' everyday lives and comprises 10 items. It evaluates neck pain and the functional status of a person with neck pain.

    Time frame: 4 weeks

Secondary outcomes

  1. Numeric Pain Rating Scale

    A numeric pain rating scale is used for pain assessment. It is an 11-point scale scored from 0-10(32); "1-3" = mild pain, "4-6" = moderate pain, "7-10" = severe pain.

    Time frame: 4 weeks

  2. Headache Intensity & Frequency

    The headache frequency and intensity have been measured using a headache diary. The patient has provided the diary, which they updated daily and in which they recorded the reduction or increase in headache pain, intensity, and frequency.

    Time frame: 4 weeks

07

Study locations

1 site
  • Dow University of Health Sciences
    Karachi, Sindh 70505, Pakistan
08

References and documents

Individual participant data

Plan to share: No — While signing the consent form with patients, it was decided that we would not share the patient data with anyone. It will remain private between the patient and the researcher.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Mar 2026, 9 months.

Of 49 non-industry interventional studies with no phase under Tension-Type Headache, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 32. This study's 9 months is above that.

Counting every sponsor, half of 49 studies reached it within 7 months; a quarter within 3 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartActual
Jun 1, 2025
Primary completionActual
Mar 31, 2026
CompletionActual
Mar 31, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951801
Responsible party
Dr. Aqsa Munir PT (Postgraduate Student, Dow University of Health Sciences) — Principal investigator
First posted
Nov 20, 2026
Start date
Jun 1, 2025
Primary completion
Mar 31, 2026
Completion
Mar 31, 2026
Last update
Nov 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion